A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
A phase 3 trial testing IBI343 in pancreatic ductal adenocarcinoma, now recruiting.
Overview
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) is a phase 3 interventional study registered as NCT07066098, led by Innovent Biologics (Suzhou), and recruiting when checked on 2026-09-11. Official title: A Multicenter, Randomised, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants With Claudin (CLDN) 18.2-Positive, Locally Advanced Unresectable or Metastatic Pancreatic Cancer Who Received>=2 Prior Lines of Therapy. Planned enrolment is 201 participants (estimated). The study started in 2025-08-04 and primary completion is expected in 2027-06-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialStudy of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Shares Innovent Biologics and the tag ctgov-ingest.
- TrialIBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Shares Innovent Biologics and the tag ctgov-ingest.
- TrialA Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment
Shares Innovent Biologics and the tag ctgov-ingest.
- TrialA Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialStudy of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.